Ireland’s Minister for Health, Simon Harris, announced this week that Ireland is seeking to join Belgium, the Netherlands, Luxembourg, and Austria in their BeNeLuxA Initiative, a group that negotiates price deals on pharmaceuticals directly with manufacturers.
Ireland’s Minister for Health, Simon Harris, announced this week that Ireland is seeking to join Belgium, the Netherlands, Luxembourg, and Austria in their BeNeLuxA Initiative, a group that negotiates price deals on pharmaceuticals directly with manufacturers.
Harris wll now issue a letter of intent to the organization to formally signal Ireland’s interest in joining the collaboration and will travel to Belgium and the Netherlands in the coming weeks to begin discussions with an aim toward joining the bloc. In a statement, Harris said that that supply and price challenges are “…not unique to Ireland, and many countries are battling with the same issues. That is why, over the past [2] years, my department has been engaging with other European countries in an effort to identify solutions to medicines pricing, sustainability, and supply.”
The BeNeLuxA bloc was formed in 2015 with the mission to foster sustainable national healthcare systems in Europe, and to address the challenge of affordability of innovative therapies. The group participates in horizon scanning (seeking information about high-cost therapies that will be become available in the near future), health technology assessments (HTAs), information sharing and policy exchange, and—critically—price negotiations with industry.
According to a discussion paper published the European Public Health Alliance (EPHA) in 2017, health ministers from the Netherlands and Belgium first saw the need for such a negotiating bloc after drug maker Gilead introduced the high-cost sofosbuvir (Sovaldi) in the European marketplace. Realizing the potential for expensive drugs to strain health systems, the founding member states felt that they needed to increase their bargaining power with drug makers.
According to EPHA, drug makers “are used to negotiating bilaterally with national governments. This puts them in a favorable position, having a panoramic overview of each of the 28 EU member states’ pharmaceutical policies, purchasing power, and willingness to pay.” At the same time, national governments lack insight into neighboring countries’ policies, creating an asymmetry of information on drug pricing.
Thus far, BeNeLuxA has not had major successes to report; in May 2017, the bloc announced that it had not been able to reach a deal with drug maker Vertex on its lumacaftor/ivacaftor drug combination for the treatment of cystic fibrosis, which, according to an HTA undertaken by BeNeLuxA, was worth 82% less than Vertex’s asking price. The governments represented by BeNeLuxA declined to supply the drug in their healthcare systems, so patients will not have access to the therapy.
Furthermore, the paper notes that there exists a concern among policy makers that drug companies may attempt to discourage efforts like BeNeLuxA by refusing to negotiate so as not to set a new precedent. EPHA suggests that, as a potential solution, “Governments might wish to respond by making the BeNeLuxA route the only available option for reimbursement of a company’s products or for some clusters of products.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.